Erectile dysfunction affects an estimated 322 million men worldwide, and the search for effective treatments has driven decades of pharmaceutical research. While PDE-5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis) dominate the treatment landscape, they are not the right fit for every man. For those who cannot take nitrate medications alongside PDE-5 inhibitors, or who prefer a centrally-acting approach, apomorphine represents a clinically studied, pharmacologically distinct alternative.
Unlike the more familiar ED medications that work directly on penile blood vessels, apomorphine works in the brain. It targets dopamine receptors in the central nervous system to trigger the neural signals that initiate erection — a fundamentally different mechanism that has attracted substantial clinical interest, generated genuine controversy, and ultimately occupied a narrow but important niche in the ED treatment spectrum.
This guide covers everything the research actually shows about apomorphine for erectile dysfunction: its mechanism of action, the clinical trial data, efficacy rates, side effects, how it compares to sildenafil head-to-head, who it may be appropriate for, and where it currently stands in clinical practice worldwide.
What Is Apomorphine?
Apomorphine is a non-opioid dopamine agonist — despite its name, it has no structural or pharmacological relationship to morphine or opioids. The “apo” prefix refers to a chemical derivative process (apomorphine is derived from morphine through dehydration), not to any opioid activity. This is an important distinction because the name generates unnecessary concern among patients encountering it for the first time.
Apomorphine activates dopamine receptors — primarily D1 and D2 subtypes — in areas of the brain responsible for coordinating sexual response. It has been used medically for over a century in various contexts: as an emetic (to induce vomiting) at high doses, and more recently as a treatment for Parkinson's disease, where its dopaminergic activity helps manage motor symptoms. In the context of erectile dysfunction, it is used at low doses specifically formulated for sublingual (under the tongue) absorption.
The sublingual formulation was marketed under the brand names Uprima (United States, by TAP Pharmaceuticals) and Ixense (Europe, by Abbott/Takeda). Uprima never received FDA approval in the US — the New Drug Application was withdrawn before approval and was never resubmitted, reportedly due to concerns about a small incidence of vasovagal syncope (fainting) observed in clinical trials. In Europe, apomorphine SL received approval and remained available in a number of countries, though its commercial footprint has been limited by the dominance of PDE-5 inhibitors in the market.
How Apomorphine Works: The Central Mechanism
Understanding why apomorphine is pharmacologically interesting requires understanding the brain-body pathway that initiates erections — because this is where apomorphine intervenes, rather than at the penile tissue level where PDE-5 inhibitors act.
Erection is not simply a local vascular event. It is initiated by a cascade of neurological signals originating in the brain. Sexual arousal activates the paraventricular nucleus (PVN) of the hypothalamus — a small but critical brain region that serves as a coordination hub for autonomic, endocrine, and behavioral responses. The PVN sends descending signals through the spinal cord to the peripheral nervous system, ultimately triggering the release of nitric oxide in penile tissue and the smooth muscle relaxation that produces an erection.
Apomorphine specifically targets this central pathway. By activating dopamine D1 and D2 receptors in the paraventricular nucleus, it amplifies the neural signal that initiates erection. As published in the Journal of Urology and confirmed across multiple clinical trials, apomorphine induces what researchers describe as “selective activation in the nucleus paraventricularis leading to erectogenic signals.”
This central mechanism has a notable clinical implication: apomorphine can produce erections without requiring audiovisual erotic stimulation, though erotic stimulation enhances its effect. In men whose erectile difficulty is primarily neurological or psychogenic — where the brain-to-body signal is disrupted rather than the local vascular machinery — apomorphine's approach to the problem is particularly logical.
The sublingual formulation was specifically engineered to achieve rapid absorption through the oral mucosa, bypassing the extensive first-pass metabolism in the liver that would otherwise render the drug ineffective when swallowed. This delivery method allows a low plasma concentration to be reached quickly — sufficient to activate the desired dopaminergic pathway in the hypothalamus while remaining below the threshold that would stimulate the chemoreceptor trigger zone (the brain's nausea center).
Clinical Trial Evidence: What the Numbers Show
Apomorphine SL was one of the most extensively studied ED compounds of its era. More than 5,000 men with erectile dysfunction participated in Phase II and Phase III clinical trials evaluating doses ranging from 2 to 6 mg, generating a substantial body of efficacy and safety data.
Phase III Efficacy Data
The primary endpoint across most trials was the percentage of sexual attempts resulting in an erection firm enough for intercourse — a direct, clinically meaningful measure. Key findings from pooled Phase III data (published in PubMed and summarized in multiple urology reviews) include:
- At the 3 mg dose, 49.4% of attempts resulted in erections firm enough for intercourse, compared to a baseline of 24.3% — roughly double the baseline success rate
- At the 2 mg dose, success rates were comparable with a marginally better tolerability profile
- Average median time to erection was 18 to 19 minutes after sublingual administration
- Average median duration of erection was approximately 13 minutes
- Partner evaluations using the Brief Sexual Function Inventory (BSFI) corroborated patient-reported outcomes
A dose-optimization study published in PubMed found that when patients were allowed to adjust from 2 mg up to 4 mg based on response, the mean percentage of attempts resulting in firm enough erections reached 39.4%, compared to 13.1% at baseline — a nearly threefold improvement over pre-treatment function.
The pooled crossover data from three placebo-controlled fixed-dose studies (involving 415 total patients) confirmed these findings consistently across different ED etiologies, including men with controlled diabetes, hypertension, benign prostatic hyperplasia, and coronary vascular disease.
The Honest Limitation
The efficacy numbers, while statistically significant and clinically meaningful for the responders, are considerably more modest than those reported for PDE-5 inhibitors. A systematic review and meta-analysis on apomorphine for ED confirmed that sublingual apomorphine is more effective than placebo at approved doses — but also acknowledged that differences from placebo were not clinically relevant in certain subpopulations, particularly men who had undergone radical prostatectomy.
This is not a minor caveat. It frames apomorphine accurately as a moderately effective treatment rather than a highly effective one — important context for managing patient expectations.
Apomorphine vs. Sildenafil: The Head-to-Head Data
The most important clinical question about apomorphine is not whether it works compared to placebo, but how it compares to the established standard of care. Multiple prospective, randomized crossover studies addressed this directly.
Journal of Urology Crossover Study
A prospective, randomized, double-blind crossover study published in the Journal of Urology compared sublingual apomorphine 3 mg against oral sildenafil 50 mg in 77 heterosexual men with ED across various etiologies and severities. The results were striking: sildenafil achieved erections firm enough for intercourse in 85% of attempts versus 44% for apomorphine (p < 0.0001). Successful intercourse rates followed the same pattern — 81% for sildenafil versus 43% for apomorphine. Erectile function domain scores on the International Index of Erectile Function (IIEF) were significantly higher for sildenafil as well.
Brazilian Multicenter Crossover Study
A multicenter crossover trial across 12 Brazilian centers enrolled 108 men with documented ED. Mean successful intercourse rates were 83.3% for sildenafil versus 40.3% for apomorphine (p < 0.001). Treatment satisfaction scores were similarly divergent. At study end, 93.8% of patients initially randomized to apomorphine declared a preference for sildenafil; 81.3% of those initially treated with sildenafil also preferred it. The authors concluded that sildenafil was significantly more effective across all measured domains.
Arteriogenic ED Subgroup Study
A comparative crossover study specifically in men with arteriogenic ED (where vascular disease restricts blood flow to the penis) published in the International Journal of Impotence Research found an overall success rate of 63.7% for sildenafil versus 32.1% for apomorphine (p < 0.01), with a higher incidence of adverse events in the apomorphine group.
The pattern across all head-to-head studies is consistent: sildenafil is significantly more effective than apomorphine for most men. However, researchers consistently noted one clinically important nuance — apomorphine does not share sildenafil's contraindication with nitrate medications. This is where apomorphine's place in clinical practice becomes more clearly defined.
The Nitrate Advantage: Apomorphine's Clinical Niche
PDE-5 inhibitors are absolutely contraindicated in men taking organic nitrates (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate) because combining these drugs can cause a profound, potentially life-threatening drop in blood pressure. Since many men with ED also have cardiovascular disease and are prescribed nitrates for chest pain or heart failure management, this contraindication eliminates PDE-5 inhibitors as an option for a meaningful subset of patients.
A systematic review and meta-analysis confirmed that sublingual apomorphine is currently the only licensed oral drug for erectile dysfunction that is not absolutely contraindicated with nitrate use. Research published in ScienceDirect specifically on cardiovascular safety concluded that apomorphine SL “is well tolerated and safe in men with ED associated with concomitant cardiovascular disorders or risk factors” and “is not contraindicated in men with stable coronary artery disease who take nitrate medication.”
A double-blind, randomized, placebo-controlled crossover trial (162 men on long-term antihypertensive medications including nitrates) found that SL apomorphine at higher-than-recommended doses produced only sporadic and clinically insignificant changes in blood pressure and heart rate. The most significant interaction observed was a modest orthostatic drop in blood pressure in the alpha-blocker and calcium channel blocker groups — but no severe cardiovascular events were recorded across the entire Phase 3 trial program.
This is a specific, important, and underappreciated clinical advantage. For men who need an oral ED treatment but cannot take PDE-5 inhibitors because of nitrate therapy, apomorphine represents a medically appropriate alternative with a meaningfully different pharmacological safety profile.
Side Effects and Safety Profile
Apomorphine's side effect profile is largely a function of its dopaminergic mechanism — the same receptor activity that produces its erectogenic effect also stimulates other dopamine-sensitive pathways.
Nausea
The most common adverse event across clinical trials was nausea, reported in approximately 7% of patients at the 3 mg dose and as high as 11.7% in dose-optimization studies. Importantly, the clinical trial data consistently showed that nausea diminished with continued dosing — men who experienced nausea on early attempts typically found it less problematic as their bodies adapted to the medication.
The sublingual formulation was specifically designed to minimize nausea by targeting a plasma concentration high enough to activate hypothalamic dopamine receptors but below the threshold that would stimulate the chemoreceptor trigger zone (the brain area that induces vomiting). This pharmacokinetic balancing act was the primary engineering challenge in developing the formulation.
Other Adverse Events
Additional side effects reported across trials include dizziness, headache, somnolence (drowsiness), and yawning — all consistent with central dopaminergic stimulation. These effects were generally dose-related and diminished over time.
Vasovagal Syncope
The most serious adverse event — and the one most responsible for the drug's regulatory difficulties in the United States — was vasovagal syncope (fainting due to a sudden drop in blood pressure). Across Phase 3 trials, the incidence was less than 0.2% of patients. While this rate is low, it was preceded by prodromal symptoms (dizziness, sweating, nausea) in virtually all cases, giving men warning before the event. No deaths or severe cardiovascular events were reported throughout the entire Phase 3 clinical trial program.
Men with resting hypotension (systolic blood pressure below 90/50 mmHg), unstable cardiovascular conditions, or significant hemodynamic instability should not use apomorphine. Men taking alpha-blockers should use it with caution due to additive blood pressure lowering effects.
Not Appropriate After Radical Prostatectomy
The meta-analysis on apomorphine for ED specifically noted that its efficacy was not clinically relevant in men who had undergone radical prostatectomy — where the nerves involved in erectile signaling may have been disrupted. Since apomorphine works through neural pathways, its central mechanism provides limited benefit when those downstream pathways are structurally compromised.
Apomorphine in Current Clinical Practice
The clinical landscape for apomorphine has evolved significantly since its initial development. Several important developments have shaped where it stands today.
Status in the United States
Sublingual apomorphine for ED is not FDA-approved in the United States. The Uprima NDA was withdrawn before approval and has not been resubmitted. However, apomorphine is available in the US as an FDA-approved injectable treatment for Parkinson's disease (Apokyn), and compounding pharmacies have increasingly produced apomorphine in troche (lozenge) formulations for sublingual ED use, often combined with sildenafil or tadalafil.
The combined apomorphine/PDE-5 inhibitor troche represents an emerging approach: apomorphine stimulates the central dopaminergic pathway to initiate erection signaling, while the PDE-5 inhibitor component acts peripherally to enhance the vascular response once that signal arrives at penile tissue. Compounding pharmacy documentation describes this as “coordinated peripheral vasodilation and central neurotransmitter release — a synergy that may benefit patients with psychogenic ED or attenuated nitric oxide signaling secondary to diabetes or endothelial dysfunction.” This combination formulation is not FDA-approved as a finished pharmaceutical product but represents a legitimate, physician-supervised approach for select patients.
Status in Europe and Other Markets
Apomorphine SL received regulatory approval in Europe under the Ixense brand and has been available in several European countries. Its market penetration has remained limited due to the efficacy gap versus PDE-5 inhibitors, but it continues to hold a clinical niche for the nitrate-taking population and men who experience unacceptable side effects from PDE-5 inhibitors.
The Fifth International Consultation on Sexual Medicine (ICSM 2024)
The 2024 ICSM guidelines acknowledged apomorphine's historical role and noted ongoing research interest in dopaminergic approaches to ED. The consultation noted that clinical exploration of dopamine receptor agonists “faced challenges, with limited clinical success compared to PDE5 inhibitors due to side effects including nausea and vomiting” — but also highlighted emerging research into selective D4 receptor agonists, which may offer the central erectogenic effect with fewer adverse events. This suggests that the dopaminergic pathway to ED treatment that apomorphine pioneered may eventually yield more refined pharmacological tools.
Who Is Apomorphine For? A Clinical Perspective
Based on the totality of the published evidence, apomorphine is most appropriately considered for the following patient profiles:
Men who cannot take PDE-5 inhibitors due to nitrate therapy. This is apomorphine's clearest and most evidence-supported clinical indication. For men with stable cardiovascular disease managed with nitrates who also experience ED, sublingual apomorphine offers an oral treatment option where no PDE-5 inhibitor can safely be used.
Men with mild to moderate psychogenic ED. Because apomorphine works through the central dopaminergic pathway — the neural circuit that coordinates sexual arousal — it may be particularly well-suited to men whose erectile difficulty is primarily psychological or performance-related rather than vascular. The drug acts at the brain level where psychological inhibition of erectile response originates.
Men who experience PDE-5 inhibitor non-response. Approximately 30–35% of men do not adequately respond to PDE-5 inhibitors for various reasons, including severe vascular disease, neurogenic dysfunction, or hormonal factors. For these men, a centrally-acting alternative with a different mechanism offers a legitimate second-line option, potentially in combination formulations.
Men who prefer rapid onset over duration. The 18–23 minute onset for sublingual apomorphine is faster than many oral PDE-5 inhibitors (excluding the rapid-dissolve tadalafil formulations). For some men, the faster time-to-effect profile is clinically preferable.
Apomorphine is not recommended as a first-line treatment for the general ED population. Men with moderate to severe organic ED, those with arteriogenic disease, and those post-prostatectomy are likely to see limited benefit compared to available alternatives.
How Apomorphine Differs from PDE-5 Inhibitors: A Summary
The differences between apomorphine and PDE-5 inhibitors are not merely a matter of degree — they reflect fundamentally different pharmacological approaches to the same problem.
Site of action: PDE-5 inhibitors act peripherally in penile tissue, blocking the enzyme that breaks down the chemical signal sustaining smooth muscle relaxation and blood inflow. Apomorphine acts centrally in the brain, amplifying the neural signal that initiates the entire erectile cascade from the top down.
Nitrate interaction: PDE-5 inhibitors are absolutely contraindicated with nitrates due to the risk of severe hypotension. Apomorphine is not contraindicated with nitrates, though caution is still warranted with long-acting nitrates due to modest additive blood pressure effects.
Efficacy in organic ED: PDE-5 inhibitors are significantly more effective in men with vascular, metabolic, or hormonal contributors to ED. Apomorphine's modest efficacy in these populations reflects its dependence on intact peripheral pathways to translate the central signal into an actual erection.
Side effect profile: PDE-5 inhibitor side effects are primarily vascular (headache, flushing, nasal congestion, visual changes). Apomorphine's side effects are primarily central/dopaminergic (nausea, dizziness, yawning, somnolence).
Spontaneous vs. erotic-dependent action: Apomorphine can produce spontaneous erections without erotic stimulation, though erotic context enhances its effect. PDE-5 inhibitors require sexual stimulation to activate the nitric oxide release that their mechanism depends on.
Practical Considerations for Men Exploring Apomorphine
Any man considering apomorphine for erectile dysfunction should approach it through a physician-supervised framework. Given that it is not FDA-approved for ED in the United States and is available primarily through compounding pharmacies when prescribed off-label, the quality and dosing of available formulations varies. Key practical points include:
Start at the lowest effective dose. Clinical trials consistently showed that 2–3 mg sublingual apomorphine offers the best efficacy-to-tolerability ratio. Higher doses (4–6 mg) increase efficacy marginally but substantially increase nausea and other adverse events.
Allow time for tolerability to improve. The nausea that some men experience early in apomorphine use typically diminishes with repeated dosing. Men who discontinue after the first experience of nausea may miss the point at which tolerability improves — a pattern specifically documented in the trial literature.
Disclose all medications. Particular attention to alpha-blockers, antihypertensives, and any cardiovascular medications is essential. The drug interaction profile is distinct from PDE-5 inhibitors, and the risk-benefit calculation differs by concomitant medication class.
Understand the nitrate nuance. While apomorphine is not absolutely contraindicated with nitrates, long-acting nitrates can cause additive blood pressure reductions. This is manageable under medical supervision but should not be dismissed.
Set realistic expectations. Apomorphine approximately doubles baseline erectile success rates for responsive patients but does not approach the efficacy of PDE-5 inhibitors for most men. Men expecting Viagra-level results will be disappointed. Men looking for a biologically distinct approach that works through the brain's own arousal circuitry — and for whom PDE-5 inhibitors are contraindicated or insufficient — may find it genuinely useful.
The Future of Central-Acting ED Treatments
Apomorphine's most enduring contribution to the ED treatment field may ultimately be conceptual rather than commercial. It established that the dopaminergic pathway in the hypothalamus is a pharmacologically viable target for erectile dysfunction — a finding that has shaped subsequent research into central-acting compounds.
Current research interest, as noted in the 2024 ICSM guidelines, has shifted toward selective dopamine D4 receptor agonists such as ABT-724, which have shown the ability to induce penile erection in animal models without triggering vomiting — potentially solving the primary tolerability limitation that constrained apomorphine's clinical adoption. If these compounds demonstrate equivalent selectivity in human studies, they may eventually offer a refined version of what apomorphine's developers originally envisioned.
Separately, the combination troche approach (apomorphine plus sildenafil or tadalafil) represents a pragmatic middle ground currently being explored through compounding pharmacy channels: using a low dose of each agent to engage both the central and peripheral mechanisms simultaneously, potentially achieving additive efficacy while keeping each component's dose below the threshold for major side effects.
Final Assessment: Apomorphine for Erectile Dysfunction
Apomorphine is a pharmacologically legitimate, clinically studied treatment for erectile dysfunction with a well-characterized mechanism, a robust body of trial evidence, and a specific clinical niche that no other currently available oral agent occupies.
The evidence clearly shows it is less effective than sildenafil for most men. The evidence also clearly shows it is the only oral ED drug that can be used in men on nitrate therapy. These two facts, taken together, define exactly where apomorphine belongs in the treatment algorithm: not as a first-line option for the general ED population, but as a medically important alternative for men who need one.
For men researching apomorphine, the key takeaway is this: the central dopaminergic mechanism is real, the clinical data is real, the nitrate compatibility advantage is real — and the lower efficacy compared to PDE-5 inhibitors is also real. Any honest assessment of apomorphine holds all four of those facts simultaneously rather than emphasizing only what is convenient.
Men experiencing erectile dysfunction should work with a qualified healthcare provider to identify whether apomorphine, a PDE-5 inhibitor, or another treatment modality is most appropriate for their specific clinical situation. ED can be an early indicator of cardiovascular and metabolic health issues warranting medical evaluation regardless of which treatment is ultimately chosen.
The information in this article is for educational purposes only and does not constitute medical advice. Apomorphine is not FDA-approved for the treatment of erectile dysfunction in the United States. Any use of apomorphine for ED should occur under physician supervision. Men experiencing erectile dysfunction should consult a qualified healthcare provider for proper diagnosis and individualized treatment recommendations.
References
- Heaton JPW. (2001). Oral treatment of erectile dysfunction with apomorphine SL. PubMed. PMID 11741126.
- Stief C, Padley RJ, Perdok RJ, Sleep DJ. Cross-study review of the clinical efficacy of apomorphine SL 2 and 3 mg: pooled data from three placebo-controlled, fixed-dose crossover studies. ScienceDirect.
- Serretta V, Almasio PL, Pavone-Macaluso M. (2004). Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. Journal of Urology. PMID 15538264.
- Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. PubMed. PMID 18537952.
- Fagan TC, Buttler S, Marbury T, Taylor A, Edmonds A. (2001). Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. ScienceDirect. PMID 11589843.
- Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis. UroToday. Published 2020.
- Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sexual Medicine Reviews. Oxford Academic.
- Apomorphine SL (Ixense, Uprima) and sexual function. Biopsychiatry.com clinical summary.
- Safety and Tolerability of Apomorphine SL in Men with Cardiovascular Disorders. ScienceDirect.
- Apomorphine for ED: Why It Fell Short and What Works Now. Urosculpt. April 2026.
- Ro Health. Apomorphine for ED: How It Works, Risks, and When to Use It. Updated December 2025.